Sitagliptin phosphate and Enalapril maleate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sitagliptin phosphate and Enalapril maleate. Common interactions include dyslipidaemia among females and cardiac failure among males.

The phase IV clinical study analyzes what interactions people who take Sitagliptin phosphate and Enalapril maleate have. It is created by eHealthMe based on reports of 44 people who take Sitagliptin phosphate and Enalapril maleate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

44 people who take Sitagliptin phosphate and Enalapril maleate together, and have interactions are studied.

What is Sitagliptin phosphate?

Sitagliptin phosphate has active ingredients of sitagliptin phosphate. eHealthMe is studying from 3,161 Sitagliptin phosphate users for its effectiveness, alternative drugs and more.

What is Enalapril maleate?

Enalapril maleate has active ingredients of enalapril maleate. It is often used in high blood pressure. eHealthMe is studying from 32,010 Enalapril maleate users for its effectiveness, alternative drugs and more.

Number of Sitagliptin phosphate and Enalapril maleate reports submitted per year:

Common Sitagliptin Phosphate and Enalapril Maleate drug interactions by gender *:

female:

Dyslipidaemia
Glycosylated haemoglobin increased
Hepatic steatosis
Accidental exposure
Accidental needle stick
Angioedema
Blood glucose increased
Bradycardia
Diabetes mellitus inadequate control
Diabetic retinopathy

male:

Cardiac failure
Dizziness
Erythema
Fatigue
Myocardial infarction
Nausea
Nephropathy toxic
Pleural effusion
Pulmonary hilum mass
Pyrexia

Common Sitagliptin Phosphate and Enalapril Maleate drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Cardiac failure
Dehydration
Dizziness
Myocardial infarction
Nephropathy toxic
Pleural effusion
Pyrexia
Accidental needle stick
Acute psychosis
Blood creatine phosphokinase increased

50-59:

Dyslipidaemia
Glycosylated haemoglobin increased
Hepatic steatosis
Cardiac failure
Leukocytoclastic vasculitis
Alcoholic liver disease
Alcoholic pancreatitis
Anaemia macrocytic
Ascites
Completed suicide

60+:

Cardiac failure
Oedema
Nausea
Pulmonary hilum mass
Renal failure chronic
Small cell lung cancer metastatic
Alanine aminotransferase increased
Altered state of consciousness
Anaphylactic reaction
Angioedema

Common conditions people have *:

Type 2 Diabetes: 19 people, 43.18%
High Blood Cholesterol: 8 people, 18.18%
Diabetes: 8 people, 18.18%
Hyperlipidaemia (presence of excess lipids in the blood): 5 people, 11.36%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 5 people, 11.36%
Cardiac Failure Chronic: 5 people, 11.36%
Insomnia (sleeplessness): 4 people, 9.09%
Enlarged Prostate: 4 people, 9.09%
Depression: 4 people, 9.09%
Back Pain: 4 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Sitagliptin phosphate and Enalapril maleate?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Liao KF, Lin CL, Lai SW, Chen WC, "Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: a population-based case-control study in Taiwan", European journal of internal medicine, 2016 Jan .
Belice T, Yuce S, Kizilkaya B, Kurt A, Cure E, "Noncardiac pulmonary edema induced by sitagliptin treatment", Journal of family medicine and primary care, 2014 Jan .
Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .
Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP, "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia?)", Dermatology online journal, 2012 Feb .